共 8 条
[1]
[2]
[3]
[4]
[5]
CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma[J] Andras Heczey;Chrystal U. Louis;Barbara Savoldo;Olga Dakhova;April Durett;Bambi Grilley;Hao Liu;Mengfeng F. Wu;Zhuyong Mei;Adrian Gee;Birju Mehta;Huimin Zhang;Nadia Mahmood;Haruko Tashiro;Helen E. Heslop;Gianpietro Dotti;Cliona M. Rooney;Malcolm K. Brenner Molecular Therapy 2017,
[6]
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma[J] Kathleen M. Mahoney;Gordon J. Freeman;David F. McDermott Clinical Therapeutics 2015,
[7]
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group; open-label; phase 2 trial[J] Jason R Westin;Fuliang Chu;Min Zhang;Luis E Fayad;Larry W Kwak;Nathan Fowler;Jorge Romaguera;Fredrick Hagemeister;Michelle Fanale;Felipe Samaniego;Lei Feng;Veerabhadran Baladandayuthapani;Zhiqiang Wang;Wencai Ma;Yanli Gao;Michael Wallace;Luis M Vence;Laszlo Radvanyi;Tariq Muzzafar;Rinat Rotem-Yehudar;R Eric Davis;Sattva S Nee
[8]
Expression and Regulation of the PD‐L1 Immunoinhibitory Molecule on Microvascular Endothelial Cells[J] Michael J.Eppihimer;JasonGunn;Gordon J.Freeman;Edward A.Greenfield;TetyanaChernova;JamieErickson;John P.Leonard Microcirculation 2010,

